Product candidates will be based on BioNTech’s proprietary mRNA technology and on Pfizer’s antigen technology. Clinical trials are expected to start in the second half of 2022
Entos will receive an initial payment of US $50 million, which includes an equity investment by Lilly
JBI-802 is a novel, oral, potent and selective dual inhibitor of two epigenetic targets of the CoREST complex: LSD1 and HDAC6
A preview on Q3FY22 by Nirmal Bang Securities on select Indian pharma companies
PeproTech's recombinant proteins portfolio complements Thermo Fisher's cell culture media products
The latest research results indicated that JMB2002 had high binding activity to the Omicron variant and showed potent Omicron pseudovirus neutralization function
The test kit is compatible with all standard Real-Time PCR machines with a test run time of 85 minutes. The result turnaround time, including sample collection and RNA extraction, is 130 minutes
The virtual world makes it possible to visualize, test, understand and predict what cannot be seen, before a patient is treated
The Academy endeavours to reach all levels of the society in creating programs that are accessible to one and all with training for Health Volunteers, Asha, Angavadi, school-teachers and students as part of life-skill development
BPZE1 is the most advanced next-generation pertussis vaccine currently in clinical development
Subscribe To Our Newsletter & Stay Updated
